



**\*\*THIS DOCUMENT IS NOT FOR DISTRIBUTION IN CHINA (PRC) EXCEPT IN COMPLIANCE WITH ALL APPLICABLE LAWS AND REGULATIONS\*\***

**\*\*ONLY FOR DISTRIBUTION TO AUSTRALIAN "EXEMPT INVESTORS" AS DEFINED IN CHAPTER 6D.2 OF THE AUSTRALIAN CORPORATIONS ACT 2001 (CTH) (CORPORATIONS ACT) OR "WHOLESALE CLIENTS" AS DEFINED IN CHAPTER 7 OF THE CORPORATIONS ACT\*\***

## **Editas Medicine, Inc.**

**("EDIT" / NASDAQ)**

**Editas Medicine, Inc. is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes.**

**Joint Bookrunners: Morgan Stanley, J.P. Morgan**

**Base Offer size: 4,000,000 Shares (100% Primary)  
Greenshoe: 15% (100% Primary)**

**Launch Date: Wednesday, March 15, 2017 (Post-Close)  
Expected Pricing Date: Thursday, March 16, 2017 (Post-Close)**

**\*\*\***

### **Group Investor Call**

**Thursday, March 16, 2017 @ 11:00 AM EST  
US: (877) 569-8703 / INTL: (706) 645-9770  
CONF ID: 88798635**

**\*\*\***

**\*\*\*THIS DOCUMENT MAY ONLY BE SENT EXTERNALLY WITH THE DISCLAIMERS INCLUDED\*\*\***

**\*\*THIS DOCUMENT IS NOT FOR DISTRIBUTION IN CANADA, JAPAN OR BRAZIL\*\***

**\*\*THIS DOCUMENT IS NOT FOR DISTRIBUTION IN CHINA (PRC) EXCEPT IN COMPLIANCE WITH ALL APPLICABLE LAWS AND REGULATIONS\*\***

**\*\*ONLY FOR DISTRIBUTION TO AUSTRALIAN "EXEMPT INVESTORS" AS DEFINED IN CHAPTER 6D.2 OF THE AUSTRALIAN CORPORATIONS ACT 2001 (CTH) (CORPORATIONS ACT) OR "WHOLESALE CLIENTS" AS DEFINED IN CHAPTER 7 OF THE CORPORATIONS ACT\*\***

The foregoing is a preliminary summary of terms and is subject to change. Please contact your Morgan Stanley representative for more details.

A registration statement relating to these securities (including a prospectus and a preliminary prospectus supplement) has been filed with the Securities and Exchange Commission (the "SEC"), which has become effective by rule of the SEC. Before you invest, you should read the prospectus and the preliminary prospectus supplement in that registration statement for more complete information about the issuer and this offering. This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities

in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement and accompanying prospectus relating to these securities may be obtained from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Not for distribution to private customers (FCA definition).

---

NOTICE: Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. If you have received this communication in error, please destroy all electronic and paper copies and notify the sender immediately. Mistransmission is not intended to waive confidentiality or privilege. Morgan Stanley reserves the right, to the extent permitted under applicable law, to monitor electronic communications. This message is subject to terms available at the following link: <http://www.morganstanley.com/disclaimers>. If you cannot access these links, please notify us by reply message and we will send the contents to you. By communicating with Morgan Stanley you consent to the foregoing and to the voice recording of conversations with personnel of Morgan Stanley.